摘要
目的 研究在老年中高危骨髓增生异常综合征(myelodysplastic syndrome, MDS)及急性髓系白血病(acute myeloid leukemia, AML)患者中联合应用地西他滨和小剂量化疗的临床效果。方法 选取2022年4月至2023年4月郑州大学第一附属医院收治的老年中高危骨髓增生异常综合征及急性髓系白血病92例患者,根据治疗方案不同分组,应用小剂量化疗的46例作为常规组,将地西他滨和小剂量化疗联用的46例作为研究组,针对两组疗效、临床指标和不良反应进行观察及比较。结果 疗效方面对比,研究组总有效率(93.48%)明显高于常规组(76.09%),组间差异有统计学意义(P<0.05)。在治疗前,两组血管内皮生长因子(VEGF)、生长分化因子11(GDF11)和可溶性转铁蛋白受体(sTfR)的水平差异无统计学意义(P>0.05),在治疗后,两组VEGF、GDF11和sTfR的水平均有所降低,且与常规组相比,研究组明显降低,差异有统计学意义(P<0.05)。在不良反应方面,常规组不良反应发生率(15.22%)和研究组(4.35%)相比差异无统计学意义(P>0.05)。结论 将地西他滨和小剂量化疗联合用于老年中高危MDS及AML患者,可表现出确切性效果。
Objective To study the clinical effect of decitabine and low dose chemotherapy combination in elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia. Methods Ninety-two elderly patients with high-risk myelodysplastic syndrome and acute myeloid leukemia admitted to the First Affiliated Hospital of Zhengzhou University from April 2022 to April 2023 were selected. According to different treatment plans, 46 patients receiving low-dose chemotherapy were selected as the conventional group, and 46 patients receiving decitabine and low-dose chemotherapy combination were selected as the study group. The efficacy, clinical indexes and adverse reactions of the two groups were observed and compared. Results In terms of efficacy, the total effective rate of the study group(93.48%) was significantly higher than that of the conventional group(76.09%), and the difference between groups was statistically significant(P<0.05). Before treatment, there was no statistical significance in the levels of vascular endothelial growth factor(VEGF), growth differentiation factor 11(GDF11) and soluble transfertransferin receptor(sTfR) between the two groups(P>0.05). After treatment, the levels of VEGF, GDF11 and sTfR were decreased between the two groups, and significantly decreased in the study group compared with the conventional group. The difference was statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the conventional group(15.22%) and the study group(4.35%)(P>0.05). Conclusions The combination of decitabine and low-dose chemotherapy in elderly patients with middle and high-risk MDS and AML can show a definite effect.
作者
任蒙蒙
孙培娟
邢伟
贾冰冰
REN Meng-meng;SUN Pei-juan;XING Wei;JIA Bing-bing(Department of Hematology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《医药论坛杂志》
2024年第3期289-292,共4页
Journal of Medical Forum
